# EDGAR Filing Document

**Accession Number:** 0001135951
**File Stem:** 0001575872-25-000508
**Filing Date:** 2025-7
**Character Count:** 9446
**Document Hash:** 94e8b10fe3c5a993c052d04258c4bd31
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001575872-25-000508.hdr.sgml**: 20250728

**ACCESSION NUMBER**: 0001575872-25-000508

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20250725

**FILED AS OF DATE**: 20250728

**DATE AS OF CHANGE**: 20250725

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DR REDDYS LABORATORIES LTD
- **CENTRAL INDEX KEY:** 0001135951
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15182
- **FILM NUMBER:** 251152797

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 8-2-337, ROAD NO.3 BANJARA HILLS
- **CITY:** HYDERABAD
- **PROVINCE COUNTRY:** K7
- **ZIP:** 500-034
- **BUSINESS PHONE:** 91 40 49002900

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 8-2-337, ROAD NO.3 BANJARA HILLS
- **CITY:** HYDERABAD
- **PROVINCE COUNTRY:** K7
- **ZIP:** 500-034

#### <br>

#### SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

Form 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16** 

#### UNDER THE SECURITIES EXCHANGE ACT OF 1934

# July 2025

# Commission File Number 1-15182

#### DR. REDDY'S LABORATORIES LIMITED
(Translation of registrant's name into English)

**8-2-337, Road No. 3, Banjara Hills**

**Hyderabad, Telangana 500 034, India**

#### +91-40-49002900
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ◻&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No ⌧

If "Yes" is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

**EXHIBITS** 

---

| | | |
|:---|:---|:---|
| **Exhibit**<br>**Number** |  | **Description of Exhibits** |
| [99.1](rdy0788_ex99-1.htm) | [](rdy0788_ex99-1.htm) | [Intimation dated July 25, 2025](rdy0788_ex99-1.htm) |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | DR. REDDY'S LABORATORIES LIMITED<br>(Registrant) | DR. REDDY'S LABORATORIES LIMITED<br>(Registrant) | DR. REDDY'S LABORATORIES LIMITED<br>(Registrant) |
| Date: July 25, 2025  | By: | /s/ K Randhir Singh | /s/ K Randhir Singh |
|  |  | Name: | K Randhir Singh |
|  |  | Title: | Company Secretary  |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| ![](rdy0788_ex99-1img01.jpg) | **Dr. Reddy's Laboratories Ltd.**<br>8-2-337, Road No. 3, Banjara Hills<br>Hyderabad – 500 034, Telangana, India<br>CIN: L85195TG1984PLC004507<br>Tel:&nbsp;&nbsp;&nbsp;&nbsp; + 91 40 4900 2900<br>Fax:&nbsp;&nbsp;&nbsp;&nbsp; + 91 40 4900 2999<br>Email: <u>mail@drreddys.com</u><br>Web:&nbsp;&nbsp;&nbsp;&nbsp;<u>www.drreddys.com</u> |

---

July 25, 2025

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd (Stock Code: DRREDDY)

Dear Sir/Madam,

---

| | |
|:---|:---|
| **Sub:** | **Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**  |

---

This is in furtherance to our intimation dated November 5, 2024, wherein we had informed that the Board has approved the fund infusion by way of investment in equity shares of Dr. Reddy's Laboratories LLC, Russia, a step-down wholly-owned subsidiary ("DRL Russia"), upto an amount of Rs.600 Crores.

In this connection, we further inform that the Company has made an investment of Rs. 565,40,77,993/- in DRL Russia for a total equity stake of 45.19%.

The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, with respect to the above fund infusion is given in Annexure enclosed herewith.

This is for your information and records.

Thanking you.

Yours faithfully,

For **Dr. Reddy's Laboratories Limited**

**K Randhir Singh** 

*Company Secretary, Compliance Officer and Head-CSR* 

Encl: as above

**Annexure** 

<u>Disclosure under Part A Para A(i) of Schedule III read with Regulation 30 of the SEBI (Listing</u>

<u>Obligation and Disclosure Requirements) Regulations, 2015</u>

---

| | | |
|:---|:---|:---|
| **Sl.** <br>**No** | &nbsp;&nbsp;&nbsp;**Particulars** | &nbsp;&nbsp;&nbsp;**Description** |
| 1 | &nbsp;&nbsp;&nbsp;Name of the target entity, details in brief such as size, turnover etc.<br>| &nbsp;&nbsp;&nbsp;Dr. Reddy's Laboratories LLC, Russia, ("DRL Russia"), a step-down wholly-owned subsidiary of the Company. The fund infused by the Company into DRL Russia will be used for working capital requirements. The turnover of DRL Russia for FY2025 was Rs. 2,347 Cr.  |
| 2 | &nbsp;&nbsp;&nbsp;Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length" | &nbsp;&nbsp;&nbsp;The investment in DRL Russia is a related party transaction, as DRL Russia is a step-down wholly owned subsidiary and accordingly a related party to the Company. Except as stated above, the promoter/ promoter group/ group companies have no interest in DRL Russia. |
| 3 | &nbsp;&nbsp;&nbsp;Industry to which the entity being acquired belongs<br>| &nbsp;&nbsp;&nbsp;DRL Russia is a Pharmaceutical company registered in Russian Federation distributing pharmaceutical medicines in the country. |
| 4 | &nbsp;&nbsp;&nbsp;Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | &nbsp;&nbsp;&nbsp;The fund infused by the Company into DRL Russia will be used for working capital requirements. |
| 5 | &nbsp;&nbsp;&nbsp;Brief details of any governmental or regulatory approvals required for the acquisition | &nbsp;&nbsp;&nbsp;Not Applicable  |
| 6 | &nbsp;&nbsp;&nbsp;Indicative time period for completion of the acquisition<br>| &nbsp;&nbsp;&nbsp;The Company has acquired total equity stake of 45.19% in DRL Russia on July 25, 2025. |
| 7 | &nbsp;&nbsp;&nbsp;Nature of consideration- whether cash consideration or share swap or any other form and details of the same | &nbsp;&nbsp;&nbsp;Cash consideration |
| 8 | &nbsp;&nbsp;&nbsp;Cost of acquisition and/or the price at which the shares are acquired<br>| &nbsp;&nbsp;&nbsp;Cash consideration of Rs. 565,40,77,993/- towards total equity stake of 45.19% in DRL Russia. |
| 9 | &nbsp;&nbsp;&nbsp;Percentage of shareholding / control acquired and / or number of shares acquired | &nbsp;&nbsp;&nbsp;DRL Russia is a step- down wholly owned subsidiary of the Company. |
| 10 | &nbsp;&nbsp;&nbsp;Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | &nbsp;&nbsp;&nbsp;DRL Russia is a Pharmaceutical company registered in Russian Federation distributing pharmaceutical medicines in the country. The company was incorporated on 5<sup>th</sup> of April 2003. The turnover of the company for the previous 3 years is shown in below table:<br>FY 2025 Rs.2347 Cr<br>FY 2024 Rs.2084 Cr<br>FY 2023 Rs.1915 Cr<br>|

---